Pronounced cancer resistance in a subterranean rodent, the blind mole-rat, Spalax: in vivo and in vitroevidence
- Irena Manov1,
- Mark Hirsh2,
- Theodore C Iancu3,
- Assaf Malik1,
- Nick Sotnichenko4,
- Mark Band5,
- Aaron Avivi†1Email author and
- Imad Shams†1Email author
© Manov et al.; licensee BioMed Central Ltd. 2013
Received: 18 April 2013
Accepted: 26 July 2013
Published: 9 August 2013
Subterranean blind mole rats (Spalax) are hypoxia tolerant (down to 3% O2), long lived (>20 years) rodents showing no clear signs of aging or aging related disorders. In 50 years of Spalax research, spontaneous tumors have never been recorded among thousands of individuals. Here we addressed the questions of (1) whether Spalax is resistant to chemically-induced tumorigenesis, and (2) whether normal fibroblasts isolated from Spalax possess tumor-suppressive activity.
Treating animals with 3-Methylcholantrene (3MCA) and 7,12-Dimethylbenz(a) anthracene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA), two potent carcinogens, confirmed Spalax high resistance to chemically induced cancers. While all mice and rats developed the expected tumors following treatment with both carcinogens, among Spalax no tumors were observed after DMBA/TPA treatment, while 3MCA induced benign fibroblastic proliferation in 2 Spalax individuals out of12, and only a single animal from the advanced age group developed malignancy 18 months post-treatment. The remaining animals are still healthy 30 months post-treatment. In vitro experiments showed an extraordinary ability of normal Spalax cultured fibroblasts to restrict malignant behavior in a broad spectrum of human-derived and in newly isolated Spalax 3MCA-induced cancer cell lines. Growth of cancer cells was inhibited by either direct interaction with Spalax fibroblasts or with soluble factors released into culture media and soft agar. This was accompanied by decreased cancer cell viability, reduced colony formation in soft agar, disturbed cell cycle progression, chromatin condensation and mitochondrial fragmentation. Cells from another cancer resistant subterranean mammal, the naked mole rat, were also tested for direct effect on cancer cells and, similar to Spalax, demonstrated anti-cancer activity. No effect on cancer cells was observed using fibroblasts from mouse, rat or Acomys. Spalax fibroblast conditioned media had no effect on proliferation of noncancerous cells.
This report provides pioneering evidence that Spalax is not only resistant to spontaneous cancer but also to experimentally induced cancer, and shows the unique ability of Spalax normal fibroblasts to inhibit growth and kill cancer cells, but not normal cells, either through direct fibroblast-cancer cell interaction or via soluble factors. Obviously, along with adaptation to hypoxia, Spalax has evolved efficient anti-cancer mechanisms yet to be elucidated. Exploring the molecular mechanisms allowing Spalax to survive in extreme environments and to escape cancer as well as to kill homologous and heterologous cancer cells may hold the key for understanding the molecular nature of host resistance to cancer and identify new anti-cancer strategies for treating humans.
Throughout the last 50 years, several thousand Spalax individuals have been housed and studied in the Animal Facility at the Institute of Evolution of Haifa University. Despite this small rodent’s (approximately 100 to 200 gr.) long lifespan (>20 years), none of the animals have ever developed spontaneous tumors, nor do they show any aging-related phenotypic changes. The mole rat, Spalax ehrenbergi, is a wild, solitary rodent of the Eastern Mediterranean region. Spalax inhabits a system of poorly ventilated, dark, sealed underground tunnels protected from climatic extremes, pathogens and predation. During the Mediterranean rainy season animals are engaged in intensive digging to collect food, mate, and repair and extend their territory under extreme hypoxic conditions. Spalax has evolved a unique adaptive complex mechanism for surviving underground, including a special ability to cope with extreme hypoxia and hypercapnia . Spalax can conduct intensive aerobic work under low O2 pressures (down to 3% O2) due to increased muscular mass, and high density of blood vessels and mitochondria, resulting in reduced oxygen diffusion distance and efficient oxygen delivery even at low capillary PO2[1, 2].
Hypoxia can result in a failure to maintain essential cellular functions and contributes to cardio- and cerebrovascular failure, pulmonary diseases and cancer, which together are the primary sources of morbidity in the Western world. A long and growing list of genes exhibits hypoxia-related adaptations in structure and function in Spalax[3–6]. Noteworthy are VEGF, constitutively highly expressed as compared to rats ; p53 that harbors substitutions in the DNA-binding site, identical to the most common p53 mutations in tumors; however, in Spalax it renders a bias against apoptosis but favors cell cycle arrest/DNA repair both in vitro and in vivo; and a unique Spalax heparanase splice variant that was shown to decrease tumor size in mice by a factor of 7 and reduce metastatic activity compared to native mice heparanase . Furthermore, assessment of Spalax transcriptome assembly and expression data has revealed enrichment of genes that overlap cancer resistance, apoptosis, angiogenesis pathways and hypoxia-tolerance [10, 11]. This suggests that Spalax is potentially resistant to malignant transformation. Elucidating the mechanisms evolved in this wild, non-inbred, naturally cancer resistant rodent should have great importance as preventative measures and may present an efficient way of dealing with increasing cancer incidence.
Tumors contain malignant cells and tumor stroma consisting of fibroblasts, extracellular matrix (ECM) and vasculature with endothelial cells [12, 13]. Cancer progression requires a permissive stromal environment in which mutant cells can survive, proliferate and invade. Fibroblasts are ubiquitous stromal cells interlinked with tumors via regulation of growth factors and cytokines, and through reassembling of the ECM . The majority of published studies report the cancer-enhancing effects of fibroblasts in their activated form [15, 16]. However, early studies from co-culture experiments indicate that normal fibroblasts may have a tumor suppressor function . Unfortunately, little attention has been given to the protective role of normal fibroblasts.
Based on our earlier observations that Spalax is resistant to spontaneous cancer, and assuming that normal fibroblasts apparently play a role in this phenomenon, we took two experimental approaches in the present study: (1) to directly confirm the hypothesis that Spalax is highly resistant to induced tumorigenesis, we used a two-step 7,12-Dimethylbenz (a) anthracene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA) skin carcinogenesis protocol , and 3-Methylcholantrene (3MCA) protocol for local fibrosarcoma induction  in mice, rats and Spalax; and (2) co-culture experiments were conducted to study the interactions between normal primary fibroblasts isolated from different rodent species (Spalax, mouse, rat, naked mole rat Heterocephalus glaber and spiny mice Acomys cahirinus), with human hepatocellular carcinoma (Hep3B and HepG2) and breast cancer cells (MDA-MB-231 and MCF7), as well as 3MCA-induced, Spalax-derived fibrosarcoma cells (SpFS2240).
We provide evidence that (1) Spalax is extremely resistant to experimentally induced cancer, and (2) Spalax’s normal fibroblasts, originated from adult or newborn animals, target tumor cells and restrict malignant behavior either through direct fibroblast-cancer cell interaction or via soluble factors produced by a monolayer of Spalax fibroblasts.
Spalaxis resistant to chemically-induced cancer
To assess experimentally if Spalax is resistant to chemically-induced carcinogenesis, we treated animals from different rodent species according to the following protocols:
A case of fibrosarcoma development in Spalax
The remaining treated Spalax individuals showed no phenotypic or behavioral changes, and were still under observation in the Animal House over two years following treatment (October 2010 to July 2013).
Spalax fibroblasts suppress growth of human cancer cells in vitro
In vitroanticancer activity by other wild, natural rodents’ fibroblasts
Conditioned medium generated by Spalaxfibroblasts induces cancer cell death, but does not affect normal primary fibroblasts
We next evaluated the reversibility of the inhibition of cancer cells initiated by Spalax CM. HepG2 and Hep3B were grown with Spalax CM for four days, then the medium was changed by either fresh unused regular media or with fresh Spalax CM. Cancer cell viability was measured after another two days. Recovery of the cancer cells was demonstrated when the CM was changed with fresh unused regular media (Figure 7D). Importantly, growth of Spalax-derived fibrosarcoma cells (SpFS2240) was gradually suppressed by CM generated by Spalax normal fibroblasts, but was not affected by normal, full medium and CM derived from Hep3B cells or CM derived from the SpFS2240 cells themselves (Figure 7E). Noteworthy, no inhibitory effects were detected on mouse, rat and Spalax normal fibroblasts following exposure to homologous or heterologous CM (Figure 7F). To get a preliminary idea of the nature of the secreted factors responsible for cancer cell growth inhibition, CM from Spalax and rat fibroblasts, and the regular medium of fibroblasts (DMEM-F12) were heated to 56°C for 10 minutes, and 30 minutes. The different heat-treated media was mixed 1:1 with RPMI (the optimal growth medium for the hepatoma cell lines used in this study) and was added to Hep3B cancer cells. After seven days, the viability of the cancer cells was measured. The heat-treated CM generated from Spalax fibroblasts reduced its anticancer activity, expressed as a partial increase in Hep3B cells viability (Figure 7G).
Soluble factors generated by Spalaxfibroblasts cause cell cycle arrest, nuclear fragmentation, and impair mitochondrial dynamics in cancer cells
Spalax normal fibroblasts inhibit colony formation in soft agar of the breast carcinoma cell lines MDA-MB-231 and MCF7 as well as Spalax-derived fibrosarcoma
Notwithstanding the importance of laboratory mice in comprehension of carcinogenesis mechanisms, this cancer-prone model organism failed to provide satisfactory knowledge of cancer preventive mechanisms and treatment strategies in humans. (http://www.safermedicines.org/quotes/cancer.shtml). Therefore, elucidating mechanisms employed by a wild, non-inbred mammal that is naturally cancer-resistant raises promising opportunities.
Spalax has been thoroughly investigated at the Institute of Evolution of Haifa University as a model for adaptation to environmental hypoxia (for example, [1, 23]). During the last decade a growing number of genes involved in hypoxic response have been studied and exhibited Spalax-specific features [4, 11]. Directly related to this study on cancer-resistance of Spalax are the tumor suppressor p53 favoring cell cycle arrest over apoptosis  and a unique Spalax heparanase splice variant that was shown to significantly decrease tumor size and metastatic activity compared to native heparanase . Furthermore, despite the extremely long lifespan of Spalax (>20 years), even after studying thousands of individuals for decades, we have never observed animals that developed spontaneous tumors, nor show any aging-related phenotypic changes.
In vivostudies of carcinogen-induced tumor
We report here that Spalax is resistant to two-stage DMBA/TPA, and 3-MCA carcinogen treatments. DMBA/TPA is commonly used to study malignant transformation, resembling formation of human squamous cell carcinoma . A single dose of DMBA induced substantial oxidative stress , and when followed by repetitive application of TPA led to persistent inflammation supporting tumorigenesis . In the present study, mice treated with DMBA/TPA initially developed benign papillomas, which subsequently transformed to squamous cell carcinomas. In contrast, treatment of Spalax led to necrotic wounds, which completely healed with no signs of malignancy. The carcinogen 3-MCA is known to produce fibrosarcomas through persistent inflammation and reactive metabolites causing severe oxidative damage . In our study, 100% of 3-MCA-injected mice and rats developed tumors at the injection site within two to three and four to six months, respectively. One year after 3MCA treatment no Spalax animals showed any pathological process. However, 2 out of 6 old individuals (from a total of 12 animals) developed benign fibrotic overgrowths after 14 and 16 months, respectively, and only one case of malignant transformation in a >10 year-old Spalax animal was recognized, 18 months after 3-MCA injection.
It is well established that oxidative stress drives tumor progression and metastasis . Thus, the mechanisms that Spalax evolved to survive hypoxia might be related to resistance to induced or spontaneous cancers. Spalax have recently been shown to have higher levels of reactive oxygen species (ROS) processing enzymes compared to hypoxia-intolerant rodents . Nrf2, a transcription factor critical for defense against oxidative stress, has a unique structure in Spalax. Whereas it is highly conserved among most mammals , Spalax Nrf2 carries 27 specific amino acid replacements, 6 within the Neh6-domain, which is critical for stabilizing the protein under ambient oxidative stress and for its transcriptional activity . Studies performed on Nrf2−/− mice have shown the essential role of Nrf2 for detoxification of DMBA metabolites and protection against DMBA-induced carcinogenesis . Unraveling the molecular mechanisms resulting in the healing of Spalax skin and inhibition of progression to tumor formation is the goal of our ongoing research. Hence, we have just initiated a comprehensive repetition of DMBA/TPA treatment where we will have a representative sample of animals from different stages following the application of this carcinogen in order to answer this question through quantification of apoptosis and senescence of Spalax skin and muscle tissue at the area of the carcinogen application. Furthermore, considering the high tolerance of Spalax to oxidative stress and the fact that DMBA is metabolized among others into ROS that cause oxidative DNA damage in the skin , the above experiment will allow us to compare the ROS levels upon DMBA application in Spalax and mice.
Another antioxidant enzyme, heme oxygenase-1 (HO-1), was shown to be elevated in Spalax tissues, and further increased under hypoxia [4, 11]. HO-1 is involved in the degradation and catabolism of heme and supports synthesis of ferritin, an iron storage protein, thus preventing oxidative damage caused by free heme and ROS . Indeed, most Spalax individuals, showing no external lesions following exposure to carcinogens, have probably resolved the initial inflammatory insult without excessive fibroplasias which can be attributed to more efficient anti-oxidation mechanisms. The benign fibroblastic proliferations observed in two 3-MCA-treated Spalax animals after 14 and 16 months suggest that Spalax is able to effectively arrest cancerous transformation. Nonetheless, whether Spalax tissues are able to prevent conversion of the 3-MCA pro-carcinogen into an active carcinogen, overcome its effect, or to inhibit previously transformed cells, remains to be clarified in future studies.
In vitro studies of Spalaxcancer resistance
Tumor growth and invasion are dependent on growth factors and cytokines produced by stromal cells . Normal stroma contains a relatively small number of fibroblasts associated with ECM. However, during wound healing, fibrosis or malignant transformations, stromal fibroblasts proliferate, intensively produce growth factors and cytokines, express α-smooth muscle actin and become cancer-associated fibroblasts (CAFs) [12, 34, 35]. CAFs are removed from the granulation tissue rapidly after healing, though in cancer stroma they persist, contributing to epithelial mesenchymal transition of cancer cells. The later phenomenon is important for cancer progression and is mediated, at least in part, by metalloproteinases secretion and ROS generation [36, 37]. Although the reports published to date have been mainly addressed to a cancer-promoting role of stromal fibroblasts, evidence suggests that normal stroma and normal fibroblasts could impede tumorigenesis [14–16, 38, 39]. Early studies  demonstrated that normal dermal fibroblasts suppressed development of malignant phenotypes of RAS-transformed keratinocytes when grafted into animals. Similarly, normal fibroblasts were able to retard melanomagenesis in its early stages . Inhibition of growth and induction of differentiation were found in breast cancer pre-neoplastic MCF10-AT1-EIII8 cells when co-cultivated with normal fibroblasts, even in the presence of estrogen . It is still unclear what events in the stroma, along with its interaction with precancerous cells, lead to a transition of the stromal function from cancer-protective to cancer-promoting, or, as in the present case of Spalax, what are the molecular mechanisms that Spalax evolved to escape cancerous transformation and to develop anti-cancer ability.
In a recent study , cancer resistance in Spalax was discussed. It was suggested that pro-growth signals originating from the fetal bovine serum, routinely added to culture medium, are conceived as cancerous transformation-like stimuli, driving Spalax fibroblast necrotic death, triggered through release of interferon-β (IFN-β). Nonetheless, in the same study, higher and earlier death rates were also shown in serum-reduced or serum-free media. Furthermore, the possibility that CM from “dying” cells may lack beneficial nutrients, or contain toxic metabolites, or other factors beyond IFN-β, was not addressed. Additionally, measurements of IFN-β in Spalax CM were performed indirectly using human cell lines . The first, VSV (Vesicular Stomatitis Virus)-GFP (encoding a Green Fluorescent Protein) gene assay, measures IFN-β expression levels by VSV-GFP reporter assay. In this assay, HT1080 cell line (human fibrosarcoma cells) had been incubated with Spalax CM, and then infected with a GFP-encoding VSV. The level of IFN-β in the media corresponds to the reduction in the number of GFP positive human HT1080 cells. In the second assay, IFN-β release by “dying” Spalax cells is determined by HEK (Human Embryo Kidney cells)-Blue cells assay. In this assay the induction of β-gal reporter in human EK cells under IFN-β-inducible promoter is measured. Both assays use human cells for indirectly measuring Spalax IFN-β, which is inconsistent with the authors’ declaration that human cells are nonresponsive to Spalax CM stimuli possibly due to species divergence of IFN-β . Likewise, no proof was given that the ability to kill “dying” fibroblasts is unique to Spalax’s CM, for example, by trying to compare the fate of the cells when grown with CM of the other species tested in the study, namely, mice or human. Additionally, the method used in this study for declaring necrotic death is based on the Annexin V/propidium iodide assay . Briefly, floating and adherent cells were harvested, stained with Annexin-V and propidium iodide, and analyzed by flow cytometery. The known disadvantage of this method is that it cannot conclusively prove that cell death is solely the result of necrosis, nor eliminate the possibility of apoptotic mechanisms. Also, the authors have not provided evidence for interrelations between their three declared observations (transformation-like stimuli, necrotic death and release of IFN-β). Overall, it is our impression that the above mentioned study  does not provide direct evidence to Spalax cancer resistance, certainly not its anti-tumor properties. Alternatively, we show here that viable, proliferating Spalax fibroblasts, from adult and newborn animals, inhibit growth of cancer cells derived from different tissues and species, most importantly human, but do not affect non-cancerous cells, including those of Spalax (Figure 7F), thereby highlighting a strategy used by Spalax to identify and target malignancies. This unique interaction is further strengthened by the observation that the growth of cancer cells is regained once the immediate interaction with Spalax cells is terminated (Figure 7D). Importantly, no inhibitory effect on cancer cell growth was found when fibroblasts from above-ground species (rat, mice and Acomys) were tested.
Recently, several studies investigated the unique cancer-resistance properties of the naked mole rat (Heterocephalus glaber), another subterranean, long-lived, rodent species. The most recent study suggested a connection between a high viscosity of media conditioned by Heterocephalus fibroblast cells due to exceptional secretion of high-molecular mass hyaluronan (HMM-HA) , which was suggested to mediate what was named by the authors “early contact inhibition”, previously described by the same group as an anticancer mechanism in Heterocephalus cells, and was initially ascribed to p16(Ink4a) and p27(Kip1) activity . In the same paper , it is reported that HMM-HA was detected also in Spalax fibroblasts even in higher levels compared to Heterocephalus fibroblasts, though no experiments were carried out to clarify its role in Spalax fibroblasts. Nevertheless, this may explain the prevalent high viscosity of the medium of cultured Spalax fibroblasts we noticed, though we find that it does not prevent Spalax cells from reaching confluence or influences their anti-cancer properties. Furthermore, CM from Spalax with apparent normal viscosity was also able to inhibit cancer cells proliferation (ongoing study). In light of the fact that hyaluronan-cancer cell interactions were shown to promote, and not inhibit, cancer invasion , the correlation between HMM-HA, the potential of cells to reach confluence and the resistance to oncogenic transformation or anti-cancer activity, requires further direct experimental support, especially in the case of our model organism, the Spalax. Another study endorsed Heterocephalus cells’ cancer-resistance to rapid cell crisis following oncogenic transformation, which is characterized by abnormal chromatin material and nuclei, leading to a failure to successfully complete cell division, hence the inability of the cells to progress into malignancy . These observations are somewhat similar to our findings of fragmented and deformed nuclei and chromatin condensation (Figure 8), disturbed cell division and proliferation (Figure 9E) of human cancer cells, as well as the 3MCA-induced Spalax and mice fibrosarcoma cell line, upon their interaction with Spalax fibroblasts. In view of the similar ability of Heterocephalus fibroblasts to kill cancer cells (Figure 6), and as the efficiency of experimental oncogenic transduction of cells is never 100%, it is possible that the Heterocephalus cells that escaped malignant transformation killed the oncogenic-transduced ones.
Our findings demonstrated that Spalax fibroblasts or their CM target human cancer cells growth machinery, triggering programmed cancer cell death (Figures 4, 5, 8 and 9). Following co-culture with Spalax fibroblasts or their CM, cancer cells (Hep3B, HepG2 and MCF7) undergo morphological changes typical of apoptosis : swelling, rounding, detachment, shrinkage and floating. Moreover, nuclear condensation and abnormal mitochondrial fission as well as accumulation of cells in sub-G1 (Figures 8 and 9) also suggest apoptotic modes of cancer cell death. BrdU incorporation, reflecting cell proliferation, confirmed that Spalax CM contains anti-proliferative factors, inhibiting cell division in a time-dependent pattern. We further showed that the effect of Spalax CM on cancer cells is transient and reversible. That is, replacing the CM with regular fresh medium leads to recovery of those cancer cells that had not been affected by the CM. Last but not least, Spalax fibroblasts presumably impair the aggressive behavior of tumor cells: the invasive phenotype of highly metastatic MDA-MB-231 breast carcinoma cells was markedly reduced (Figure 10). Noteworthy, the ability to form colonies in soft agar by 3MCA-induced, Spalax-derived fibrosarcoma was significantly suppressed by homologous fibroblasts, whereas heterologous fibroblasts (rat and mouse) increased tumor formation (Figure 11). Spalax fibroblasts also inhibited colony formation in soft agar by 3MCA-induced, mouse-derived fibrosarcoma.
In order to strengthen our findings of Spalax cells’ anti-cancer activity, compared to cells from laboratory, in-bred, aboveground mice and rats, we decided to follow the cancer activity pattern of two other, wild, out-bred, species. Hence, fibroblast cells were propagated from the aboveground, wild, short-lived rodent Acomys, and the subterranean, wild, long-lived Heterocephalus. We have shown here that, similar to Spalax cells, Heterocephalus fibroblasts restrict growth and effectively kill cancer cells, while Acomys cells behave similarly to rat and mice, that is, have no anti-cancer activity (Figure 6). We may assume that this anti-cancer ability might be shared by species living under extreme conditions and adapted to stress, such as hypoxia, which is directly related to cancer initiation and progression. It would be interesting to investigate this phenomenon in other hypoxia-tolerant species, such as other subterranean, high altitude and diving mammals.
Previous studies showed that key hypoxia-regulatory genes in stromal fibroblasts, such as HIF1-α and VEGF, negatively influence tumorigenesis . HIF1-α is a known tumor-promoting transcription factor in most malignancies ; however, its expression in tumor stromal fibroblasts could suppress cancer cell growth . We have previously shown that HIF1-α as well as ROS-scavenging enzymes  are constitutively highly expressed in Spalax. Similar to our explanations of the failure to induce cancer in vivo in live Spalax animals, in vitro studies, using fibroblast cells, demonstrated a significant role in adaptive response to oxidative stress, at least in part, via expression of HO-1 . High levels of mitochondrial ROS produced by cancer cells were shown to drive tumor development via remodeling of the stromal environment and enhancing invasion. Recently, the roles of ROS produced by fibroblasts in their trans-differentiation to myofibroblasts and in cancer cell invasiveness were reported . ROS-generating CM of mutated fibroblasts promoted metastasis of A375 melanoma through the increasing of ROS and HIF1-α stabilization in melanoma cells. However, when N-acetyl cysteine, a ROS scavenger, was added to the system, HIF1-α accumulation and melanoma cell invasion were inhibited .
Adaptive tolerance to hypoxia stress in Spalax, both in vivo and in vitro, may grant the unique resistance to cancer through strong antioxidant mechanisms, among others (for example, as mentioned here, the unique activity of its p53  and heparanse ), that quench ROS before they spread and damage DNA and other macromolecules, thus providing cellular homeostasis and cancer protection. As such, they are a milestone in our efforts in understanding the mechanisms by which the long-lived, hypoxia-tolerant Spalax hinders cancer initiation and progression.
Collectively, we have shown here an outstanding cancer resistance of the whole, live Spalax, and not just in cultured cells, and anticancer activity of Spalax cells on human cancer cells, and not just resisting transformation of its own healthy cells. This phenomenon extensively described here using different methodologies on cells from different ages of Spalax, together with our initial observation of a similar ability of cells originated from another subterranean, long-lived, hypoxia- and cancer-resistant animal, the Heterocephalus, highlight the importance to adopt such animal models with exceptional genetic-embedded tolerance to environmental stress, in cancer research.
Our ongoing research is focused on identifying the factors secreted by Spalax cells, and their selective interaction with cancer cells to suppress tumorigenesis. Our first step to exploring the nature of the secreted factors was the heat-inactivation preliminary experiment presented here (Figure 7G). The heat treatment of Spalax CM caused only partial loss of the anti-cancer activity of Spalax-generated CM. Although not conclusive, this may indicate the involvement of protein factors in the observed phenomenon. We are also studying the signaling mechanisms and death receptors whose activation triggers cancer cell death. These studies will hopefully contribute to the identification of new anti-cancer mechanisms and future tumor preventive or therapeutic strategies. To our knowledge, the present study demonstrates, for the first time, Spalax tolerance to chemically induced carcinogenesis along with direct anticancer effect of Spalax fibroblasts on human cancer cells.
During 50 years of studies, with thousands of animals that crossed our Animal House, we have never observed spontaneous tumors in Spalax. Similar phenomenon was observed also in another subterranean long-lived rodent, Heterocephalus. Based on this observation, a few studies [41, 42, 44] have tried to explain cancer resistance in Heterocephalus through testing known molecular mechanisms of malignant transformation on healthy fibroblast cells. Though different molecular mechanisms were suggested, none of these studies dealt with anti-cancer properties of the whole, live animal in vivo, or on the direct interaction of its normal cells with cancer cells. Hence, our presentation is a pioneering, genuine, breakthrough study. We have tried to induce cancer in Spalax with chemical carcinogens that induced cancer in 100% of mice and rats, and the results allow us to state that Spalax is extremely resistant not only to spontaneous cancer but also to induced cancer. Furthermore, fibroblast cells from Spalax inhibit growth and kill cancer cells from various species and cell lines. This is exhibited in both the co-culture system or by exposure to conditioned media harvested from Spalax fibroblasts. Cancer cell death was accompanied by decreased cancer cell viability and proliferation, reduced colony formation in soft agar, disturbed cell cycle progression, chromatin condensation, nuclei deformation and mitochondrial fragmentation.
This phenomenon is prominent in Spalax fibroblasts, regardless of the animal age, from newborns a few days old to animals over 10 years old, as proved by the reversibility of cancer cells death, once their immediate interaction with Spalax fibroblasts is terminated. The anti-cancer activity of Spalax is specific to cancer cells and not to normal cells. It may be shared by other stress-adapted mammals as we initially showed here by co-culturing Heterocephalus fibroblasts with cancer cells that also leads to cancer cell death.
“The classical mice model for cancer research has little predictive value and a negligible relation to that of human. Far more than anything else, the lack of good animal models has become the rate-limiting step in human cancer research” (Prof. Robert Weinberg, MIT; Newsweek, September 6th, 2008). Therefore, it would be extremely useful to study naturally cancer-resistant animals, as models to find ways to prevent cancer before it occurs. Our results may lead to a breakthrough in the conservative paradigm of cancer research, completely dependent on laboratory, inbred rodents, and place Spalax as the ‘missing’, appropriate candidate model for such studies. We anticipate that the long lived, hypoxia- and cancer-tolerant Spalax will turn out to be a significant biological resource to biomedical research as a model organism for understanding cancer and its prevention.
All animal protocols were approved by the Institutional Ethics Committee.
Blind mole-rat (Spalax), rats (Rattus norvegicus) and C57BL/6 mice were subjected to DMBA/TPA or 3MCA treatments. For DMBA/TPA treatment, eight Spalax and six mice were used. For 3MCA treatment 12 Spalax, 6 mice and 6 rats were used. Spalax and Acomys were captured in the field and housed under ambient conditions in individual cages in the Animal Facility of the Institute of Evolution, University of Haifa. Noteworthy, Spalax do not undergo uniform acclimatization upon transfer from their natural habitat to a standardized laboratory environment but rather behave differentially according to their eco-geographic origins . The C57BL/6 mice were purchased from Harlan Laboratories (Jerusalem, Israel). Rats were supplied by the Animal House of the Psychology Department of Haifa University. Heterocephalus was a gift from Tisch Family Zoological Gardens in Jerusalem. All animals were kept with free access to food and water at 21 to 23°C in a 12:12 light-dark cycle. All animals used for experiments were healthy. Animals were sacrificed with an inhalation anesthesia agent (isoflurane) overdose.
Four Spalax individuals approximately 2 years old and four individuals over 10 years old; and six individuals of C57BL/6 mice, 3 to 4 months old, were used in the 7,12-Dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA) experiments. A single application of 200 μg of DMBA dissolved in 100 μl of acetone for mice, and 500 μg in 250 μl for Spalax was used. The solution was applied onto the shaved back skin of the animal. Three days after the initial DMBA dose, mice were treated with 30 μg of TPA (Sigma Aldrich, Inc.) dissolved in 100 μl of acetone, and Spalax with 60 μg of TPA dissolved in 250 μl of acetone. TPA was applied three times per week for two to three months, until all mice developed advanced cancer and were subsequently sacrificed. Spalax continued to be treated for an additional three months twice a week.
3-MCA carcinogen treatment
3-methylcholanthrene (3-MCA) has been commonly used for induction of tumors in rodents . In this experimental system, mice and rats develop local fibrosarcomas in two to three and four to six months, respectively . The recommended dose of 3MCA (Sigma Aldrich, Inc.) for treatment of mice is 200 μg dissolved in 200 μl of olive oil [20, 51]. We calculated the amount applied to rats and Spalax according to their average weight. Hence, animals were treated with a single injection of 3MCA as follows: 200 μg/200 μl for mice; 1 mg/500 μl for Spalax; and 1.5 mg/500 μl for rats. Animals used in this experiment were: six approximately 2-year-old Spalax individuals; six 10-year old or older Spalax individuals; six 3- to 4- month-old mice; and six 3-month-old white rats. Animals were observed once a week until tumors could be palpated, and then two to three times a week. Animals were sacrificed; tissues were removed for cell isolation or fixation. For histological examination, the samples were fixed in 4% paraformaldehyde dissolved in PBS, dehydrated in increasing concentrations of ethanol, and embedded in paraffin. Five-micrometer sections were cut from paraffin blocks and routinely stained with hematoxylin and eosin for microscopic examination.
Primary Spalax, mice, rat, Acomys and Heterocephalus fibroblasts were isolated from under arm skin and lungs as described , and grown in DMEM-F12 medium (Biological Industries, Beit Haemeq, Israel), supplemented with 15% fetal bovine serum (FBS). Human cancer cell lines Hep3B and HepG2 (hepatoma-derived), MCF7 and MDA-MB-231 (breast cancer cells) were obtained from ATCC, and were grown in RPMI (Hep3B, HepG2) and DMEM (MCF7, MDA-MB-231) supplemented with 10% FBS, L-glutamine, penicillin and streptomycin (Biological Industries). Cells were incubated in a humidified atmosphere of 5% CO2 and 95% ambient air at 37°C. Spalax-derived fibrosarcoma cells were isolated from a tumor developed after 3MCA injection. Tumor specimens were minced and treated with 1 mg/ml of collagenase (Sigma-Aldrich) under aseptic conditions to obtain a single-cell suspension, which was plated in culture dishes in DMEM-F12 medium supplemented with 15% FBS and penicillin-streptomycin-amphotericin B solution. Cells were serially cultured more than 40 times.
Co-cultures of cancer cells and fibroblasts
Normal fibroblasts and human-derived cancer cells were co-plated in six-well plates in 2 ml of culture medium RPMI or DMEM/DMEM-F12 (1:1) supplemented with 15% FBS. Fibroblasts were plated first (5 × 104), and cancer cells were added within 1 h (5 × 103), with a 10:1 fibroblast-to-cancer cell ratio. In parallel, control cultures of cancer cells and fibroblasts were plated at the same number of cells. The medium was changed every three days. Fibroblast-cancer cell co-interactions were observed and photographed by using an inverted microscope (Optika XDS2, Italy).
Generation of conditioned media
Normal fibroblasts or cancer cells (1 × 106 cells) were plated in 10-cm tissue culture dishes and cultured in full medium containing 10% FBS for four days; thereafter, media were collected and cells were removed by centrifugation. The cell-free supernatants were then diluted with the appropriate fresh culture medium (1:1) and used for further experiments. Trypan-blue standard treatment followed by cell count using a Countess® automatic cell counter (Life Technologies), and PrestoBlue® dye reagent (Invitrogen) (as described in ) were used to investigate the viability of cancer cells exposed to CM of normal fibroblasts from different species. For BrdU incorporation assay, Cell Proliferation ELISA (Exalpha) was used following the manufacturer’s instruction.
Soft agar colony formation assay
Colony formation assay was performed as described . In brief, 2 × 105 fibroblasts were seeded in 35-mm culture dishes and cultured for two to three days to reach confluence. After washing with PBS, 1 ml of 0.5% agar in DMEM-F12 containing 2% FBS was added on top of the fibroblasts to form a base layer. After the agar was solidified, 5 × 105 cancer cells were suspended in 1 ml of 0.35% agar in DMEM containing 5% FBS and then added into the dish to form a cancer cell layer. Visible colonies were studied and photographed under phase-contrast microscope. Finally, colonies larger than 50 μm were counted. At least 10 fields on each plate duplicate were used for counting at a magnification of × 40. For total colony area, five fields were analyzed using ImageJ software .
Cell cycle analysis
The cell cycle distribution was assessed by flow cytometry of propidium iodide (PI)-stained nuclei as described previously . In brief, following incubation, cells were harvested by trypsin, combined with medium containing floating cells, washed with PBS and stained with hypotonic PI solution (PI 50 μg/ml in 0.1% sodium citrate and 0.1% Triton X-100). The PI fluorescence of individual nuclei was recorded by FACSaria (Becton Dickinson, NJ, USA). A total of 10,000 events were acquired and corrected for debris and aggregate population.
Nuclear and mitochondrial staining
Cells grown on cover slips were stained with MitoTracker®Red CM-XRos (Life Technologies) at 37°C in a humidified 5% CO2 atmosphere for 15 minutes and fixed with 3.7% formaldehyde in culture medium for another 15 minutes at 37°C. After washing with PBS twice, nuclei were counterstained with DAPI. Images were acquired with a fluorescence microscope.
Transmission electron microscopy
For transmission electron microscopy, specimens were fixed in 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.2), postfixed with 2% OsO4, dehydrated in ethanol series and embedded in epoxy resin. Semi-thin sections were stained with 1% Toluidine Blue. Ultrathin sections (60 nm) were cut with a diamond knife, placed on 300-mesh copper grids, stained with 1% uranyl acetate, and viewed and photographed with a transmission electron microscope (Technai T12, FEI).
Dulbecco’s modified Eagle medium
Fetal bovine serum
Green fluorescent protein
Human embryo kidney cells assay
Hypoxia-inducible factor 1 alpha
Reactive oxygen species
Vascular endothelial growth factor
Vesicular stomatitis virus.
This study was partially supported by Israel Cancer Association (ICA) grant (# 20130065) to AA and MH, and by The Caesarea Edmond Benjamin de Rothschild Foundation Institute for Interdisciplinary Science (C.R.I.) to IS. IM was supported by the Ministry of Immigration Absorption and the Committee for Planning and Budgeting of the Council for Higher Education, Israel, within the framework of the KAMEA program, and, in part, by Dan David Foundation. We wish to thank Mrs. Alma Joel, Mrs. Yulia Pollak, Dr. Sagie Schif-Zuck and Dr. Olga Raskina for their assistance, Dr. Nili Avni-Magen for supplying the Heterocephalus, and Prof. Abraham Korol for his dedicated support and fruitful discussions.
- Nevo E, Ivanitskaya E, Beiles A: Adaptive Radiation of Blind Subterranean Mole Rats. 2001, Leiden: Backhuys
- Shams I, Avivi A, Nevo E: Oxygen and carbon dioxide fluctuations in burrows of subterranean blind mole rats indicate tolerance to hypoxic-hypercapnic stresses. Comp Biochem Physiol A Mol Integr Physiol. 2005, 142: 376-382. 10.1016/j.cbpa.2005.09.003.View ArticlePubMed
- Ravid O, Shams I, Ben Califa N, Nevo E, Avivi A, Neumann D: An extracellular region of the erythropoietin receptor of the subterranean blind mole rat Spalax enhances receptor maturation. Proc Natl Acad Sci U S A. 2007, 104: 14360-14365. 10.1073/pnas.0706777104.PubMed CentralView ArticlePubMed
- Schulke S, Dreidax D, Malik A, Burmester T, Nevo E, Band M, Avivi A, Hankeln T: Living with stress: regulation of antioxidant defense genes in the subterranean, hypoxia-tolerant mole rat, Spalax. Gene. 2012, 500: 199-206. 10.1016/j.gene.2012.03.019.View ArticlePubMed
- Shams I, Nevo E, Avivi A: Ontogenetic expression of erythropoietin and hypoxia-inducible factor-1 alpha genes in subterranean blind mole rats. FASEB J. 2005, 19: 307-309.PubMed
- Avivi A, Gerlach F, Joel A, Reuss S, Burmester T, Nevo E, Hankeln T: Neuroglobin, cytoglobin, and myoglobin contribute to hypoxia adaptation of the subterranean mole rat Spalax. Proc Natl Acad Sci U S A. 2010, 107: 21570-21575. 10.1073/pnas.1015379107.PubMed CentralView ArticlePubMed
- Avivi A, Shams I, Joel A, Lache O, Levy AP, Nevo E: Increased blood vessel density provides the mole rat physiological tolerance to its hypoxic subterranean habitat. FASEB J. 2005, 19: 1314-1316.PubMed
- Avivi A, Ashur-Fabian O, Joel A, Trakhtenbrot L, Adamsky K, Goldstein I, Amariglio N, Rechavi G, Nevo E: P53 in blind subterranean mole rats–loss-of-function versus gain-of-function activities on newly cloned Spalax target genes. Oncogene. 2007, 26: 2507-2512. 10.1038/sj.onc.1210045.View ArticlePubMed
- Nasser NJ, Avivi A, Shafat I, Edovitsky E, Zcharia E, Ilan N, Vlodavsky I, Nevo E: Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasis. Proc Natl Acad Sci U S A. 2009, 106: 2253-2258. 10.1073/pnas.0812846106.PubMed CentralView ArticlePubMed
- Malik A, Korol A, Hubner S, Hernandez AG, Thimmapuram J, Ali S, Glaser F, Paz A, Avivi A, Band M: Transcriptome sequencing of the blind subterranean mole rat, Spalax galili: utility and potential for the discovery of novel evolutionary patterns. PLoS One. 2011, 6: e21227-10.1371/journal.pone.0021227.PubMed CentralView ArticlePubMed
- Malik A, Korol A, Weber M, Hankeln T, Avivi A, Band M: Transcriptome analysis of the Spalax hypoxia survival response includes suppression of apoptosis and tight control of angiogenesis. BMC Genomics. 2012, 13: 615-10.1186/1471-2164-13-615.PubMed CentralView ArticlePubMed
- Bremnes RM, Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, Camps C, Marinez I, Busund LT: The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thoracic Oncol Off Pub Int Assoc Study Lung Cancer. 2011, 6: 209-217.
- Egeblad M, Nakasone ES, Werb Z: Tumors as organs: complex tissues that interface with the entire organism. Dev Cell. 2010, 18: 884-901. 10.1016/j.devcel.2010.05.012.PubMed CentralView ArticlePubMed
- Angeli F, Koumakis G, Chen MC, Kumar S, Delinassios JG: Role of stromal fibroblasts in cancer: promoting or impeding?. Tumour Biol. 2009, 30: 109-120. 10.1159/000218708.View ArticlePubMed
- Dotto GP, Weinberg RA, Ariza A: Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells. Proc Natl Acad Sci U S A. 1988, 85: 6389-6393. 10.1073/pnas.85.17.6389.PubMed CentralView ArticlePubMed
- Proia DA, Kuperwasser C: Stroma: tumor agonist or antagonist. Cell Cycle. 2005, 4: 1022-1025. 10.4161/cc.4.8.1903.View ArticlePubMed
- Goerttler K, Loehrke H, Hesse B, Schweizer J: Skin tumor formation in the European hamster (Cricetus cricetus L.) after topical initiation with 7,12-dimethylbenz[a]anthracene (DMBA) and promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA). Carcinogenesis. 1984, 5: 521-524. 10.1093/carcin/5.4.521.View ArticlePubMed
- de Visser KE, Coussens LM: The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol. 2006, 13: 118-137.View ArticlePubMed
- Goerttler K, Loehrke H, Schweizer J, Hesse B: Diterpene ester-mediated two-stage carcinogenesis. Carcinog Compr Surv. 1982, 7: 75-83.PubMed
- Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, Huszar M, Iwakura Y, Segal S, Dinarello CA, Apte RN: Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 2007, 67: 1062-1071. 10.1158/0008-5472.CAN-06-2956.View ArticlePubMed
- Antonescu CR, Baren A: Spectrum of low-grade fibrosarcomas: a comparative ultrastructural analysis of low-grade myxofibrosarcoma and fibromyxoid sarcoma. Ultrastruct Pathol. 2004, 28: 321-332. 10.1080/019131290882259.View ArticlePubMed
- Buffenstein R: Negligible senescence in the longest living rodent, the naked mole-rat: insights from a successfully aging species. J Comp Physiol B. 2008, 178: 439-445. 10.1007/s00360-007-0237-5.View ArticlePubMed
- Shams I, Avivi A, Nevo E: Hypoxic stress tolerance of the blind subterranean mole rat: expression of erythropoietin and hypoxia-inducible factor 1 alpha. Proc Natl Acad Sci U S A. 2004, 101: 9698-9703. 10.1073/pnas.0403540101.PubMed CentralView ArticlePubMed
- Avivi A, Ashur-Fabian O, Amariglio N, Nevo E, Rechavi G: p53 - a key player in tumoral and evolutionary adaptation: a lesson from the Israeli blind subterranean mole rat. Cell Cycle. 2005, 4: 368-372. 10.4161/cc.4.3.1534.View ArticlePubMed
- Yuspa SH: The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis. J Dermatol Sci. 1998, 17: 1-7. 10.1016/S0923-1811(97)00071-6.View ArticlePubMed
- Izzotti A, Camoirano A, Cartiglia C, Grubbs CJ, Lubet RA, Kelloff GJ, De Flora S: Patterns of DNA adduct formation in liver and mammary epithelial cells of rats treated with 7,12-dimethylbenz(a)anthracene, and selective effects of chemopreventive agents. Cancer Res. 1999, 59: 4285-4290.PubMed
- Flesher JW, Horn J, Lehner AF: Carcinogenicity of 1-hydroxy-3-methylcholanthrene and its electrophilic sulfate ester 1-sulfooxy-3-methylcholanthrene in Sprague-Dawley rats. Biochem Biophys Res Commun. 1998, 243: 30-35. 10.1006/bbrc.1997.8048.View ArticlePubMed
- Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, Nakada K, Honma Y, Hayashi J: ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science. 2008, 320: 661-664. 10.1126/science.1156906.View ArticlePubMed
- Nioi P, Nguyen T, Sherratt PJ, Pickett CB: The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation. Mol Cell Biol. 2005, 25: 10895-10906. 10.1128/MCB.25.24.10895-10906.2005.PubMed CentralView ArticlePubMed
- Pearson KJ, Lewis KN, Price NL, Chang JW, Perez E, Cascajo MV, Tamashiro KL, Poosala S, Csiszar A, Ungvari Z, Kensler TW, Yamamoto M, Egan JM, Longo DL, Ingram DK, Navas P, de Cabo R: Nrf2 mediates cancer protection but not prolongevity induced by caloric restriction. Proc Natl Acad Sci U S A. 2008, 105: 2325-2330. 10.1073/pnas.0712162105.PubMed CentralView ArticlePubMed
- Frenkel K, Wei L, Wei H: 7,12-dimethylbenz[a]anthracene induces oxidative DNA modification in vivo. Free Rad Biol Med. 1995, 19: 373-380. 10.1016/0891-5849(95)00046-Z.View ArticlePubMed
- Soares MP, Bach FH: Heme oxygenase-1: from biology to therapeutic potential. Trends Mol Med. 2009, 15: 50-58. 10.1016/j.molmed.2008.12.004.View ArticlePubMed
- Joyce JA, Pollard JW: Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009, 9: 239-252. 10.1038/nrc2618.PubMed CentralView ArticlePubMed
- Schafer M, Werner S: Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol. 2008, 9: 628-638. 10.1038/nrm2455.View ArticlePubMed
- Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer. 2006, 6: 392-401. 10.1038/nrc1877.View ArticlePubMed
- Eyden B, Banerjee SS, Shenjere P, Fisher C: The myofibroblast and its tumours. J Clin Pathol. 2009, 62: 236-249. 10.1136/jcp.2008.061630.View ArticlePubMed
- Taddei ML, Giannoni E, Raugei G, Scacco S, Sardanelli AM, Papa S, Chiarugi P: Mitochondrial oxidative stress due to complex I dysfunction promotes fibroblast activation and melanoma cell invasiveness. J Signal Transduct. 2012, 2012: 684592-PubMed CentralView ArticlePubMed
- Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS: Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A. 1991, 88: 6028-6032. 10.1073/pnas.88.14.6028.PubMed CentralView ArticlePubMed
- Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait L: Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res. 2001, 61: 1320-1326.PubMed
- Gorbunova V, Hine C, Tian X, Ablaeva J, Gudkov AV, Nevo E, Seluanov A: Cancer resistance in the blind mole rat is mediated by concerted necrotic cell death mechanism. Proc Natl Acad Sci U S A. 2012, 109: 19392-19396. 10.1073/pnas.1217211109.PubMed CentralView ArticlePubMed
- Tian X, Azpurua J, Hine C, Vaidya A, Myakishev-Rempel M, Ablaeva J, Mao Z, Nevo E, Gorbunova V, Seluanov A: High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature. 2013, 499: 346-349. 10.1038/nature12234.PubMed CentralView ArticlePubMed
- Seluanov A, Hine C, Azpurua J, Feigenson M, Bozzella M, Mao Z, Catania KC, Gorbunova V: Hypersensitivity to contact inhibition provides a clue to cancer resistance of naked mole-rat. Proc Natl Acad Sci U S A. 2009, 106: 19352-19357. 10.1073/pnas.0905252106.PubMed CentralView ArticlePubMed
- Simpson MA, Lokeshwar VB: Hyaluronan and hyaluronidase in genitourinary tumors. Front Biosci. 2008, 13: 5664-5680.PubMed CentralView ArticlePubMed
- Liang S, Mele J, Wu Y, Buffenstein R, Hornsby PJ: Resistance to experimental tumorigenesis in cells of a long-lived mammal, the naked mole-rat (Heterocephalus glaber). Aging Cell. 2010, 9: 626-635. 10.1111/j.1474-9726.2010.00588.x.PubMed CentralView ArticlePubMed
- Desjardins LM, MacManus JP: An adherent cell model to study different stages of apoptosis. Exp Cell Res. 1995, 216: 380-387. 10.1006/excr.1995.1048.View ArticlePubMed
- Kim JW, Evans C, Weidemann A, Takeda N, Lee YS, Stockmann C, Branco-Price C, Brandberg F, Leone G, Ostrowski MC, Johnson RS: Loss of fibroblast HIF-1alpha accelerates tumorigenesis. Cancer Res. 2012, 72: 3187-3195. 10.1158/0008-5472.CAN-12-0534.PubMed CentralView ArticlePubMed
- Poon E, Harris AL, Ashcroft M: Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med. 2009, 11: e26-View ArticlePubMed
- Vile GF, Basu-Modak S, Waltner C, Tyrrell RM: Heme oxygenase 1 mediates an adaptive response to oxidative stress in human skin fibroblasts. Proc Natl Acad Sci U S A. 1994, 91: 2607-2610. 10.1073/pnas.91.7.2607.PubMed CentralView ArticlePubMed
- Nevo E: Mosaic Evolution of Subterranean Mammals: Regression, Progression and Global Convergence. 1999, Oxford, UK: Oxford University Press
- Malins DC, Anderson KM, Gilman NK, Green VM, Barker EA, Hellstrom KE: Development of a cancer DNA phenotype prior to tumor formation. Proc Natl Acad Sci U S A. 2004, 101: 10721-10725. 10.1073/pnas.0403888101.PubMed CentralView ArticlePubMed
- Slaga TJ, Gleason GL, Hardin L: Comparison of the skin tumor initiating activity of 3-methylcholanthrene and 3,11-dimethylcholanthrene in mice. Cancer Lett. 1979, 7: 97-102. 10.1016/S0304-3835(79)80102-0.View ArticlePubMed
- Glaysher S, Cree IA: Isolation and culture of colon cancer cells and cell lines. Cancer Cell Culture. Edited by: Cree IA. 2011, Portsmouth, UK: Humana Press, 135-140. 2View Article
- Manov I, Hirsh M, Iancu TC: N-acetylcysteine does not protect HepG2 cells against acetaminophen-induced apoptosis. Basic Clin Pharmacol Toxicol. 2004, 94: 213-225.View ArticlePubMed
- Tyan SW, Kuo WH, Huang CK, Pan CC, Shew JY, Chang KJ, Lee EY, Lee WH: Breast cancer cells induce cancer-associated fibroblasts to secrete hepatocyte growth factor to enhance breast tumorigenesis. PLoS One. 2011, 6: e15313-10.1371/journal.pone.0015313.PubMed CentralView ArticlePubMed
- Schneider CA, Rasband WS, Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012, 9: 671-675. 10.1038/nmeth.2089.View ArticlePubMed
- Manov I, Hirsh M, Iancu TC: Acetaminophen hepatotoxicity and mechanisms of its protection by N-acetylcysteine: a study of Hep3B cells. Exp Toxicol Pathol. 2002, 53: 489-500. 10.1078/0940-2993-00215.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.